Blog
RSS FeedPosted by Michael Wonder on 15 Feb 2022
NICE recommends new diagnostic devices for men with suspected prostate cancer in draft guidance
15 February 2022 - Four new diagnostic devices for men with suspected prostate cancer, which reduce the chances of biopsy related ...
Posted by Michael Wonder on 13 Feb 2022
How is NICE supporting digital health technology developers?
10 February 2022 - From sensor-enabled glasses that facilitate self-management for major depression to devices that measure muscle performance to ...
Posted by Michael Wonder on 13 Feb 2022
First young children now taking life changing cystic fibrosis treatment on NHS
12 February 2022 - One of the first children to receive the game changing cystic fibrosis treatment, Kaftrio, on the ...
Posted by Michael Wonder on 10 Feb 2022
New life-extending drug for advanced womb cancer to be rolled out on the NHS
8 February 2022 - A 30 minute treatment, the first of its kind for advanced womb cancer, is being rolled ...
Posted by Michael Wonder on 09 Feb 2022
Topic selection process in health technology assessment agencies around the world: a systematic review
7 February 2022 - The purpose of this study was to systematically review the process for topic selection by health technology ...
Posted by Michael Wonder on 09 Feb 2022
NICE terminates yet another appraisal of daratumumab
9 December 2022 - NICE has attempted to appraise daratumumab six times; three have had to be terminated. ...
Posted by Michael Wonder on 09 Feb 2022
More than 100 people a year in England could benefit from new endometrial cancer treatment within the Cancer Drugs Fund
8 February 2022 - Innovative new drug for treating endometrial cancer in adults recommended by NICE as an option for use ...
Posted by Michael Wonder on 08 Feb 2022
NICE misses golden opportunity to enhance access to innovative cancer drugs
7 February 2022 - Cancer patients will miss out on exciting new treatments after NICE passed up a golden opportunity ...
Posted by Michael Wonder on 08 Feb 2022
NICE recommends new drug for people living with obesity
8 February 2022 - Thousands of people living with obesity are set to benefit from a new drug which has helped ...
Posted by Michael Wonder on 07 Feb 2022
Not so NICE: cancer patients miss out on innovative new treatments
7 February 2022 - Institute for Cancer Research highlights missed opportunity for NICE to reform its cancer drug assessment processes ...
Posted by Michael Wonder on 04 Feb 2022
First gene therapy for rare genetic neurodegenerative disorder in children, recommended in NICE draft guidance
4 February 2022 - Children with a rare, fatal, genetic disorder will be able to benefit from a new one-off treatment ...
Posted by Michael Wonder on 04 Feb 2022
Libmedly: world's 'most expensive' drug recommended for NHS use
4 February 2022 - The NHS has struck a confidential deal for what's thought to be the most expensive drug ...
Posted by Michael Wonder on 03 Feb 2022
Britain fines firms $47 million over price surge for NHS nausea pill
3 February 2022 - Britain's competition watchdog on Thursday fined five firms a total of 35 million pounds ($47.5 million) ...
Posted by Michael Wonder on 03 Feb 2022
Timely intervention: first chronic kidney disease treatment in 20 years
3 February 2022 - Significant landmark as NICE recommends AstraZeneca's chronic kidney disease treatment Forxiga ...
Posted by Michael Wonder on 03 Feb 2022
Addressing uncertainty in relative effectiveness assessments by HTA organisations
31 January 2022 - This study outlines the ways in which different health technology assessment organizations deal with uncertainty in relative ...